Dean Najarian

459 total citations
14 papers, 315 citations indexed

About

Dean Najarian is a scholar working on Psychiatry and Mental health, Pediatrics, Perinatology and Child Health and Philosophy. According to data from OpenAlex, Dean Najarian has authored 14 papers receiving a total of 315 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Psychiatry and Mental health, 6 papers in Pediatrics, Perinatology and Child Health and 4 papers in Philosophy. Recurrent topics in Dean Najarian's work include Schizophrenia research and treatment (11 papers), Pharmaceutical studies and practices (5 papers) and Mental Health and Psychiatry (4 papers). Dean Najarian is often cited by papers focused on Schizophrenia research and treatment (11 papers), Pharmaceutical studies and practices (5 papers) and Mental Health and Psychiatry (4 papers). Dean Najarian collaborates with scholars based in United States, Switzerland and Italy. Dean Najarian's co-authors include Robert L. Dufresne, David N. Osser, Srihari Gopal, Jennifer Kern Sliwa, Christoph U. Correll, Stephen R. Saklad, Jordan R. Covvey, Barbara G. Wells, Jerry McKee and Charles F. Caley and has published in prestigious journals such as The Journal of Clinical Psychiatry, The International Journal of Neuropsychopharmacology and European Psychiatry.

In The Last Decade

Dean Najarian

14 papers receiving 293 citations

Peers

Dean Najarian

PMH

EDM

PHYSI

PHARM

PPCH

Ari Jaffe United States

W. Kerselaers United States

Ruey‐Hua Wang United States

Ann M. Hamer United States

Thea Moore United States

Nataša Cerovac Serbia

Peter G. Dorson United States

Fuminari Misawa Japan

Mevhibe Tümüklü Türkiye

Ole Schjerning Denmark

Ari Jaffe United States

Dean Najarian

305 ×1.3

PMH

83 ×1.3

EDM

33 ×0.6

PHYSI

63 ×1.5

PHARM

43 ×1.2

PPCH

Citations per year, relative to Dean Najarian Dean Najarian (= 1×) peers Ari Jaffe

Countries citing papers authored by Dean Najarian

Since Specialization

Citations

This map shows the geographic impact of Dean Najarian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dean Najarian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dean Najarian more than expected).

Fields of papers citing papers by Dean Najarian

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dean Najarian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dean Najarian. The network helps show where Dean Najarian may publish in the future.

Co-authorship network of co-authors of Dean Najarian

This figure shows the co-authorship network connecting the top 25 collaborators of Dean Najarian. A scholar is included among the top collaborators of Dean Najarian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dean Najarian. Dean Najarian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Alphs, Larry, Martha Sajatovic, Ibrahim Turkoz, et al.. (2023). Earlier Use of Long-Acting Injectable Paliperidone Palmitate Versus Oral Antipsychotics in Patients With Schizophrenia. The Journal of Clinical Psychiatry. 84(6). 2 indexed citations

Benson, Carmela, Dean Najarian, Steven Wang, et al.. (2023). The Effect of Longer Dosing Intervals for Long-Acting Injectable Antipsychotics on Outcomes in Schizophrenia. Neuropsychiatric Disease and Treatment. Volume 19. 531–545. 20 indexed citations

Najarian, Dean, et al.. (2023). Long-Term Efficacy and Safety of Paliperidone 6-Month Formulation: An Open-Label 2-Year Extension of a 1-Year Double-Blind Study in Adult Participants With Schizophrenia. The International Journal of Neuropsychopharmacology. 26(8). 537–544. 9 indexed citations

Najarian, Dean, et al.. (2023). Long-term efficacy and safety of paliperidone 6-month formulation: An open-label extension of a double-blind study in adult patients with schizophrenia. European Psychiatry. 66(S1). S136–S136. 2 indexed citations

Turkoz, Ibrahim, Mehmet Daskiran, H. Lynn Starr, et al.. (2022). Comparing Relapse Rates in Real-World Patients with Schizophrenia Who Were Adequately versus Not Adequately Treated with Paliperidone Palmitate Once-Monthly Injections Before Transitioning to Once-Every-3-Months Injections. Neuropsychiatric Disease and Treatment. Volume 18. 1927–1937. 2 indexed citations

Fife, Daniel, et al.. (2022). Baseline risk characterization of early versus later adopters of long‐acting paliperidone palmitate formulations. Neuropsychopharmacology Reports. 42(3). 347–351. 1 indexed citations

Najarian, Dean, Panna Sanga, Steven Wang, et al.. (2021). A Randomized, Double-Blind, Multicenter, Noninferiority Study Comparing Paliperidone Palmitate 6-Month Versus the 3-Month Long-Acting Injectable in Patients With Schizophrenia. The International Journal of Neuropsychopharmacology. 25(3). 238–251. 36 indexed citations

Sliwa, Jennifer Kern, Adam Savitz, Isaac Nuamah, et al.. (2018). An assessment of injection site reaction and injection site pain of 1-month and 3-month long-acting injectable formulations of paliperidone palmitate. Perspectives In Psychiatric Care. 54(4). 530–538. 11 indexed citations

Correll, Christoph U., Jennifer Kern Sliwa, Dean Najarian, & Stephen R. Saklad. (2018). Practical considerations for managing breakthrough psychosis and symptomatic worsening in patients with schizophrenia on long-acting injectable antipsychotics. CNS Spectrums. 24(4). 354–370. 18 indexed citations

10.

Giannetti, Vincent J., Charles F. Caley, Khalid M. Kamal, et al.. (2018). Community pharmacists and mental illness: a survey of service provision, stigma, attitudes and beliefs. International Journal of Clinical Pharmacy. 40(5). 1096–1105. 33 indexed citations

11.

Mathews, Maju, Isaac Nuamah, Adam Savitz, et al.. (2018). Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate. Neuropsychiatric Disease and Treatment. Volume 14. 2807–2816. 7 indexed citations

12.

Mathews, Maju, Isaac Nuamah, Adam Savitz, et al.. (2016). PM410. Comparison of 3-Monthly versus 1-Monthly Paliperidone Palmitate for Time to Onset and Time to Resolution of Extrapyramidal Symptoms in Patients with Exacerbated Schizophrenia. The International Journal of Neuropsychopharmacology. 19(Suppl_1). 49–49. 3 indexed citations

13.

Elefant, Erica, Jennifer Kern Sliwa, Adam Savitz, et al.. (2016). PM386. An Assessment of Injection Site Reactions and Injection Site Pain of Once-Every One Month and Three-Month Long-Acting Injectable Formulations of Paliperidone Palmitate. The International Journal of Neuropsychopharmacology. 19(Suppl_1). 41–41. 1 indexed citations

14.

Osser, David N., Dean Najarian, & Robert L. Dufresne. (1999). Olanzapine Increases Weight and Serum Triglyceride Levels. The Journal of Clinical Psychiatry. 60(11). 767–770. 170 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact